Aridis Pharmaceuticals (ARDS) Competitors $0.0002 0.00 (0.00%) As of 10/17/2025 11:37 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsSEC FilingsShort InterestTrendsBuy This Stock ARDS vs. VRPX, SMFL, SCPS, VAXX, TRVN, NAVB, GNCAQ, GNCA, STAB, and EVLOShould you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Virpax Pharmaceuticals (VRPX), Smart for Life (SMFL), Scopus BioPharma (SCPS), Vaxxinity (VAXX), Trevena (TRVN), Navidea Biopharmaceuticals (NAVB), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), and Evelo Biosciences (EVLO). These companies are all part of the "pharmaceutical products" industry. Aridis Pharmaceuticals vs. Its Competitors Virpax Pharmaceuticals Smart for Life Scopus BioPharma Vaxxinity Trevena Navidea Biopharmaceuticals Genocea Biosciences Genocea Biosciences Statera Biopharma Evelo Biosciences Virpax Pharmaceuticals (NASDAQ:VRPX) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk. Which has stronger earnings & valuation, VRPX or ARDS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVirpax PharmaceuticalsN/AN/A-$15.19MN/AN/AAridis PharmaceuticalsN/AN/A-$30.37MN/AN/A Do insiders & institutionals believe in VRPX or ARDS? 32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media refer more to VRPX or ARDS? In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score. Company Overall Sentiment Virpax Pharmaceuticals Neutral Aridis Pharmaceuticals Neutral Is VRPX or ARDS more profitable? Aridis Pharmaceuticals' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Virpax PharmaceuticalsN/A -1,554.34% -338.29% Aridis Pharmaceuticals N/A N/A N/A Which has more volatility and risk, VRPX or ARDS? Virpax Pharmaceuticals has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 38.37, meaning that its stock price is 3,737% more volatile than the S&P 500. SummaryAridis Pharmaceuticals beats Virpax Pharmaceuticals on 4 of the 6 factors compared between the two stocks. Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARDS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart ARDS vs. The Competition Export to ExcelMetricAridis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$11K$1.08B$6.21B$10.55BDividend YieldN/A4.84%5.70%4.81%P/E RatioN/A1.3285.7027.13Price / SalesN/A31.08615.42134.14Price / CashN/A17.6337.1060.81Price / BookN/A8.0712.236.52Net Income-$30.37M-$7.36M$3.33B$276.93M7 Day PerformanceN/A-1.73%1.17%1.93%1 Month PerformanceN/A28.41%6.85%2.19%1 Year PerformanceN/A-12.09%58.93%34.62% Aridis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDSAridis PharmaceuticalsN/A$0.00flatN/AN/A$11KN/A0.0030VRPXVirpax Pharmaceuticals0.2154 of 5 stars$0.02flatN/A-99.9%$26KN/A0.007SMFLSmart for LifeN/A$0.00flatN/A-87.7%$19K$11.11M0.00110Gap DownSCPSScopus BioPharmaN/A$0.00-70.0%N/AN/A$13KN/A0.009VAXXVaxxinityN/A$0.00flatN/A-50.0%$13KN/A0.0090Gap UpHigh Trading VolumeTRVNTrevena1.4576 of 5 stars$0.01flat$5.00+41,566.7%-99.4%$12K$443K0.0040NAVBNavidea BiopharmaceuticalsN/AN/AN/AN/A$10K$8.13K0.0010GNCAQGenocea BiosciencesN/AN/AN/AN/A$6KN/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6K$1.91M0.0070STABStatera BiopharmaN/A$0.00-50.0%N/AN/A$5KN/A0.0020Gap UpEVLOEvelo BiosciencesN/A$0.00flatN/A-33.3%$4KN/A0.00120News CoverageOptions VolumeGap Down Related Companies and Tools Related Companies VRPX Alternatives SMFL Alternatives SCPS Alternatives VAXX Alternatives TRVN Alternatives NAVB Alternatives GNCAQ Alternatives GNCA Alternatives STAB Alternatives EVLO Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARDS) was last updated on 10/19/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
